Restart the Phase 1 study of ALXN1720
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Jul 2020
- Due
- 31 Dec 2020
- Delivered
- August 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Due to COVID-19, the study was temporarily paused but is planned to restart in the third quarter of this year.”
What we found
Evidence strength A What the grades mean
The company successfully re-initiated the Phase 1 study of ALXN1720 in August 2020, which falls within the third quarter of 2020 deadline.
-
A Alexion Pharmaceuticals 10-Q filed 2020-10-29
“This trial was paused due to the COVID-19 pandemic, but was re-initiated in August 2020.” ✓ confirmed on the page
Checked 21 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Restart
- Deliverable
- Phase 1 study of ALXN1720
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-C899866-019402 · Corrections policy